This study presents a comprehensive approach for assessing multiple quality attributes of antibody-oligonucleotide conjugates ...

Pharma industry experts indicate that strategy in 2026 is shifting to agentic AI, sustainable efficiency, and resilient supply chains to manage tariffs, regulations, and digitalization.

Genmab shifts to innovation-led growth with 21% revenue, 52% operating profit, $3.4B cash, Epkinly, Rina-S, and Anthropic AI ...

GovCIO is proud to mark the successful early deployment of Phase 1 of the Readiness and Employment System (RES), a major milestone in the Department of Veterans Affairs (VA) ongoing modernization of ...

Carta Healthcare, the award-winning leader in enterprise clinical data management, today underscored the role of hybrid intelligence in advancing responsible AI for healthcare as Anthropic unveiled ...

Biologically, how the GLP-1 is delivered into the body should make little difference: It’s the same peptide, just in a ...

Biopharma enters 2026 amid continuing scientific progress and accelerating deal activity, yet its business model is under pressure across every facet of the value chain. Investors are taking note: ...

Drs. Gulden Menderes and Levent Mutlu, gynecological oncologists with Health First Medical Group, stress to women to speak up.

Consider five potentially undervalued stocks for 2026, including Intel, Ford, Vodafone, Pfizer and Bank of America. Learn ...

The number of children who need Japanese language tutoring is increasing in schools in the nation. As the nationalities of ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can precisely ...

Antibody-drug conjugates have emerged as one of the most popular treatment modalities for investment in recent years. Following Pfizer’s proposed move for Seagen, Ben Hargreaves tracked how the field ...